Literature DB >> 24783024

Radioactive iodine activities for postsurgical thyroid ablation: the lower the better.

Furio Pacini1.   

Abstract

Entities:  

Year:  2013        PMID： 24783024      PMCID： PMC3821491          DOI： 10.1159/000346154

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN： 2235-0640


× No keyword cloud information.
  13 in total

1.  Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?

Authors:  A F Cailleux; E Baudin; J P Travagli; M Ricard; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.

Authors:  R Michael Tuttle; Norma Lopez; Rebecca Leboeuf; Shaye M Minkowitz; Ravinder Grewal; Matvey Brokhin; Gal Omry; Steve Larson
Journal:  Thyroid       Date:  2010-03       Impact factor: 6.568

5.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Authors:  Ujjal Mallick; Clive Harmer; Beng Yap; Jonathan Wadsley; Susan Clarke; Laura Moss; Alice Nicol; Penelope M Clark; Kate Farnell; Ralph McCready; James Smellie; Jayne A Franklyn; Rhys John; Christopher M Nutting; Kate Newbold; Catherine Lemon; Georgina Gerrard; Abdel Abdel-Hamid; John Hardman; Elena Macias; Tom Roques; Stephen Whitaker; Rengarajan Vijayan; Pablo Alvarez; Sandy Beare; Sharon Forsyth; Latha Kadalayil; Allan Hackshaw
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

6.  Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.

Authors:  F Pacini; M Capezzone; R Elisei; C Ceccarelli; D Taddei; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

7.  Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.

Authors:  M Chianelli; V Todino; F M Graziano; C Panunzi; D Pace; R Guglielmi; A Signore; E Papini
Journal:  Eur J Endocrinol       Date:  2008-12-12       Impact factor: 6.664

8.  Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.

Authors:  R Elisei; M Schlumberger; A Driedger; C Reiners; R T Kloos; S I Sherman; B Haugen; C Corone; E Molinaro; L Grasso; S Leboulleux; I Rachinsky; M Luster; M Lassmann; N L Busaidy; R L Wahl; F Pacini; S Y Cho; J Magner; A Pinchera; P W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2009-10-22       Impact factor: 5.958

9.  Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.

Authors:  R Michael Tuttle; Matvey Brokhin; Gal Omry; Andrew J Martorella; Steven M Larson; Ravinder K Grewal; Martin Fleisher; Richard J Robbins
Journal:  J Nucl Med       Date:  2008-04-15       Impact factor: 10.057

10.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.

Authors:  Tania Pilli; Ernesto Brianzoni; Francesca Capoccetti; Maria Grazia Castagna; Sara Fattori; Angela Poggiu; Gloria Rossi; Francesca Ferretti; Elisa Guarino; Luca Burroni; Angelo Vattimo; Claudia Cipri; Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2007-07-03       Impact factor: 5.958
View more
  2 in total

1.  Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option.

Authors:  Jérôme Clerc; Frederik A Verburg; Anca M Avram; Luca Giovanella; Elif Hindié; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

2.  Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study.

Authors:  Rie Kanamori; Shiho Yamane; Takeshi Seto
Journal:  Adv Ther       Date:  2021-08-13       Impact factor: 3.845
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.